Pharma-Bio Serv director reports estate share transfer
SPINDEL HOWARD reported disposition transactions in this Form 4 filing.
Rhea-AI Filing Summary
SPINDEL HOWARD reported disposition transactions in this Form 4 filing.
Pharma-Bio Serv, Inc. director Howard Spindel reported an estate-related restructuring of holdings in the company’s common stock. On 2026-06-09, 42,504 shares previously reported as indirectly owned through his spouse were transferred to the couple’s adult children at $0.00 per share. Following this transfer, Spindel reports 0 shares of common stock owned. He expressly disclaims beneficial ownership of the transferred shares, stating this report should not be deemed an admission that he is their beneficial owner for Section 16 or any other purpose.
Positive
- None.
Negative
- None.
Insider Trade Summary
Other: 42,504 shares
Other
2 txns
Insider
SPINDEL HOWARD
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Common Stock F1 | 42,504 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 0 shares (Indirect, By Spouse);
Common Stock — 0 shares (Direct)
Footnotes (1)
- F1. Following the death of the reporting person's spouse, such shares were transferred to the reporting person's adult children. The reporting person disclaims beneficial ownership of these shares, and this report should not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
Key Figures
Shares transferred: 42,504 shares
Transaction price per share: $0.00
Shares owned after transaction: 0 shares
+1 more
4 metrics
Shares transferred
42,504 shares
Common stock transferred from indirect spousal ownership to adult children
Transaction price per share
$0.00
Reported price for the 42,504-share transfer on 2026-06-09
Shares owned after transaction
0 shares
Total Pharma-Bio Serv common stock reported following the transfer
Transaction date
2026-06-09
Date of the estate-related restructuring coded as transaction type J
Key Terms
beneficial ownership, Section 16, indirect, reporting person, +1 more
5 terms
beneficial ownership regulatory
"The reporting person disclaims <b>beneficial ownership</b> of these shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"beneficial owner of these shares for purposes of <b>Section 16</b>"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
indirect financial
"Shares were previously reported as <b>indirect</b> ownership "By Spouse""
reporting person regulatory
"Following the death of the <b>reporting person</b>'s spouse, such shares were transferred"
other acquisition or disposition regulatory
"Transaction code J indicates an <b>other acquisition or disposition</b>"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Pharma-Bio Serv (PBSV) director Howard Spindel report in this Form 4?
Howard Spindel reported an estate-related transfer of 42,504 shares of Pharma-Bio Serv common stock previously attributed to his late spouse. The shares moved to the couple’s adult children, and Spindel now reports 0 shares owned while explicitly disclaiming beneficial ownership of the transferred shares.
Was this Pharma-Bio Serv (PBSV) transaction a market sale or purchase?
No, it was not a market sale or purchase. The filing uses Form 4 code J, indicating an “other” type of disposition, with a reported price of $0.00 per share, reflecting an estate-related transfer of shares to the reporting person’s adult children.
Was the Pharma-Bio Serv (PBSV) transaction under a Rule 10b5-1 trading plan?
No. The Form 4’s Rule 10b5-1 checkbox is shown as not checked, and the footnote does not describe any pre-arranged trading plan. The transaction is characterized instead as a transfer following the death of the reporting person’s spouse.
What does “beneficial ownership” mean in this Pharma-Bio Serv (PBSV) filing?
In this context, “beneficial ownership” refers to having economic or voting power over shares. The director states he disclaims beneficial ownership of the 42,504 transferred shares, and the report should not be taken as admitting he is their beneficial owner under Section 16.
AI-generated analysis. How Rhea-AI works. Not financial advice.
